MIRM — Mirum Pharmaceuticals Balance Sheet
0.000.00%
- $3.69bn
- $3.70bn
- $336.89m
- 83
- 19
- 94
- 73
Annual balance sheet for Mirum Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 232 | 157 | 152 | 286 | 280 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | 3.27 | 24 | 68 | 78.3 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 236 | 167 | 190 | 388 | 393 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3.24 | 2.55 | 2.35 | 1.99 | 9.81 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 241 | 295 | 353 | 647 | 671 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 18.5 | 42.6 | 64.7 | 87.1 | 127 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 68.8 | 174 | 211 | 398 | 445 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 172 | 120 | 142 | 249 | 226 |
| Total Liabilities & Shareholders' Equity | 241 | 295 | 353 | 647 | 671 |
| Total Common Shares Outstanding |